APP and Alzheimer disease: Similarly, targeted overexpression of ACE to monocytic cells in the bigenic APP/PS1 mouse model of AD markedly reduced both soluble and insoluble levels of Aβ42, limited plaques and astrogliosis, and preserved cognitive function [145, 191].